Impact of prior antibiotics on infected pancreatic necrosis microbiology in ICU patients: a retrospective cohort study

Charlotte Garret, Emmanuel Canet, Stéphane Corvec, David Boutoille, Matthieu Péron, Isabelle Archambeaud, Aurélie Le Thuaut, Jean-Baptiste Lascarrou, Frédéric Douane, Marc Lerhun, Nicolas Regenet, Emmanuel Coron, Jean Reignier, Charlotte Garret, Emmanuel Canet, Stéphane Corvec, David Boutoille, Matthieu Péron, Isabelle Archambeaud, Aurélie Le Thuaut, Jean-Baptiste Lascarrou, Frédéric Douane, Marc Lerhun, Nicolas Regenet, Emmanuel Coron, Jean Reignier

Abstract

Background: Recent guidelines advise against prophylactic antibiotics in patients with necrotizing pancreatitis, advocating instead a step-up drainage and necrosectomy strategy with antibiotics as dictated by microbiological findings. However, prompt antibiotic therapy is recommended in patients with sepsis or septic shock, a possible presentation of infected pancreatic necrosis (IPN). Consequently, in many critically ill patients with IPN, pancreatic samples are collected only after broad-spectrum antibiotic therapy initiation. Whether this prior antibiotic exposure alters the microbiological findings is unknown. The main objective was to determine whether prior antibiotic exposure sterilized the samples collected during procedures for suspected IPN in patients admitted to the intensive care unit (ICU) for acute pancreatitis with suspected IPN. We retrospectively studied 56 consecutive ICU patients admitted with suspected IPN. We collected details on the microbiological samples and antimicrobials used. A definite diagnosis of IPN was given when bacteria were identified in pancreatic samples.

Results: In all, 137 pancreatic samples were collected, including 91 (66.4%) after antibiotic therapy initiation. IPN was confirmed in 48 (86%) patients. The proportion of positive samples was 74 (81.3%) in antibiotic-exposed patients and 32/46 (69.5%) in unexposed patients (p = 0.58). Of the 74 positive samples from exposed patients, 62 (84%) had organisms susceptible to the antibiotics used. One-third of samples contained more than one organism. Among patients with IPN, 37.5% had positive blood cultures. Multidrug- or extensively drug-resistant bacteria were identified at some point in half the patients. Enterobacter cloacae complex was more frequent in the exposed group (p = 0.02), as were Gram-negative anaerobic bacteria (p = 0.03).

Conclusion: Antibiotic exposure before sampling did not seem to affect culture positivity of pancreatic samples to confirm IPN, but may affect microbiological findings. Our results suggest that, in patients with sepsis and suspected IPN, antibiotics should be started immediately and pancreatic samples obtained as soon as possible thereafter. In other situations, antibiotics can be withheld until the microbiological results of pancreatic samples are available, to ensure accurate targeting of the spectrum to bacterial susceptibility patterns. ClinicalTrials.gov number NCT03253861.

Keywords: Acute pancreatitis; Infected pancreatic necrosis; Multidrug-resistant infection; Step-up approach.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Patient flowchart

References

    1. Forsmark CE, SwaroopVege S, Wilcox CM. Acute pancreatitis. N Engl J Med. 2016;375(20):1972–1981.
    1. Zerem E. Treatment of severe acute pancreatitis and its complications. World J Gastroenterol. 2014;20(38):13879–13892.
    1. Garret C, Péron M, Reignier J, Le Thuaut A, Lascarrou J-B, Douane F, et al. Risk factors and outcomes of infected pancreatic necrosis: retrospective cohort of 148 patients admitted to the ICU for acute pancreatitis. United Eur Gastroenterol J. 2018;6(6):910–918.
    1. Pezzilli R, Zerbi A, Campra D, Capurso G, Golfieri R, Arcidiacono PG, et al. Consensus guidelines on severe acute pancreatitis. Dig Liver Dis. 2015;47(7):532–543.
    1. Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatol Off J Int Assoc Pancreatol IAP Al. août 2013;13(4 Suppl 2):e1–15.
    1. Sekimoto M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, et al. JPN Guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis. J Hepatobiliary Pancreat Surg. 2006;13(1):10–24.
    1. Arvanitakis M, Dumonceau J-M, Albert J, Badaoui A, Bali MA, Barthet M, et al. Endoscopic management of acute necrotizing pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) evidence-based multidisciplinary guidelines. Endoscopy. 2018;50(5):524–546.
    1. Leppäniemi A, Tolonen M, Tarasconi A, Segovia-Lohse H, Gamberini E, Kirkpatrick AW, et al. 2019 WSES guidelines for the management of severe acute pancreatitis. World J Emerg Surg. 2019;14:27.
    1. van Santvoort HC, Besselink MG, Bakker OJ, Hofker HS, Boermeester MA, Dejong CH, et al. A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med. 2010;362(16):1491–1502.
    1. van Brunschot S, van Grinsven J, van Santvoort HC, Bakker OJ, Besselink MG, Boermeester MA, et al. Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial. Lancet. 2017;391(10115):51–58.
    1. Lim CLL, Lee W, Liew YX, Tang SSL, Chlebicki MP, Kwa ALH. Role of antibiotic prophylaxis in necrotizing pancreatitis: a meta-analysis. J Gastrointest Surg. 2015;19(3):480–491.
    1. Isenmann R, Rünzi M, Kron M, Kahl S, Kraus D, Jung N, et al. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial. Gastroenterology. 2004;126(4):997–1004.
    1. Villatoro E, Mulla M, Larvin M. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev. 2010 doi: 10.1002/14651858.CD002941.pub3.
    1. Isayama H, Nakai Y, Rerknimitr R, Khor C, Lau J, Wang H-P, et al. Asian consensus statements on endoscopic management of walled-off necrosis. Part 2: Endoscopic management: Asian consensus on endoscopic management of WON. J Gastroenterol Hepatol. 2016;31(9):1555–1565.
    1. Yokoe M, Takada T, Mayumi T, Yoshida M, Isaji S, Wada K, et al. Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015. J Hepato-Biliary-Pancreat Sci. 2015;22(6):405–432.
    1. Greenberg JA, Hsu J, Bawazeer M, Marshall J, Friedrich JO, Nathens A, et al. Clinical practice guideline: management of acute pancreatitis. Can J Surg. 2016;59(2):128–140.
    1. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304–377.
    1. Schubert S, Dalhoff A. Activity of Moxifloxacin, Imipenem, and Ertapenem against Escherichia coli, Enterobacter cloacae, Enterococcus faecalis, and Bacteroides fragilis in monocultures and mixed cultures in an in vitro pharmacokinetic/pharmacodynamic model simulating concentrations in the human pancreas. Antimicrob Agents Chemother. 2012;56(12):6434–6436.
    1. Wacke R, Forster S, Adam U, Mundkowski RG, Klar E, Hopt UT, et al. Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. J Antimicrob Chemother. 2006;58(5):994–999.
    1. GonzálezLópez J, MacíasGarcía F, LariñoNoia J, DomínguezMuñoz JE. Theoretical approach to local infusion of antibiotics for infected pancreatic necrosis. Pancreatology. 2016;16(5):719–725.
    1. Bassi C, Pederzoli P, Vesentini S, Falconi M, Bonora A, Abbas H, et al. Behavior of antibiotics during human necrotizing pancreatitis. Antimicrob Agents Chemother. 1994;38(4):830–836.
    1. Ikawa K, Kondo N, Nakashima A, Yoshizawa K, Morikawa N, Ikeda K, et al. Penetration of meropenem into human pancreatic juice. Scand J Infect Dis. 2013;45(5):404–406.
    1. Delcenserie R, Dellion-Lozinguez MP, Yzet T, Lepointe B, Hary L, Badoui R, et al. Pancreatic concentrations of cefepime. J Antimicrob Chemother. 2001;47(5):711–713.
    1. Papagoras D, Giamarellos-Bourboulis EJ, Kanara M, Douridas G, Paraskevopoulos I, Antzaklis G, et al. Pancreatic concentrations of cefepime in experimental necrotizing pancreatitis. J Chemother. 2003;15(1):43–46.
    1. Sağlamkaya U, Mas MR, Yaşar M, Simşek I, Mas NN, Kocabalkan F. Penetration of meropenem and cefepim into pancreatic tissue during the course of experimental acute pancreatitis. Pancreas. 2002;24(3):264–268.
    1. Gloor B, Worni M, Strobel O, Uhl W, Tcholakov O, Müller CA, et al. Cefepime tissue penetration in experimental acute pancreatitis. Pancreas. 2003;26(2):117–121.
    1. De Waele JJ, Vogelaers D, Hoste E, Blot S, Colardyn F. Emergence of antibiotic resistance in infected pancreatic necrosis. Arch Surg. 2004;139(12):1371–1375.
    1. Lee H-S, Lee SK, Park DH, Lee SS, Seo DW, Kim MH, et al. Emergence of multidrug resistant infection in patients with severe acute pancreatitis. Pancreatol Off J Int Assoc Pancreatol. 2014;14(6):450–453.
    1. Timsit J-F, Harbarth S, Carlet J. De-escalation as a potential way of reducing antibiotic use and antimicrobial resistance in ICU. Intensive Care Med. 2014;40(10):1580–1582.
    1. Bassetti M, De Waele JJ, Eggimann P, Garnacho-Montero J, Kahlmeter G, Menichetti F, et al. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med. 2015;41(5):776–795.
    1. Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care. 2011;1:47.
    1. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102–111.
    1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2012;18(3):268–281.
    1. Garret C, Péron M, Reignier J, Coron E. Risk factors and outcomes of infected pancreatic necrosis: retrospective cohort of 148 patients admitted to the ICU for acute pancreatitis. UEG J. 2018;6(6):910–918.
    1. Barrie J, Jamdar S, Smith N, McPherson SJ, Siriwardena AK, O’Reilly DA. Mis-use of antibiotics in acute pancreatitis: insights from the United Kingdom’s National Confidential Enquiry into patient outcome and death (NCEPOD) survey of acute pancreatitis. Pancreatol Off J Int Assoc Pancreatol. 2018;18(7):721–726.
    1. Sahar N, Kozarek RA, Kanji ZS, Chihara S, Gan SI, Irani S, et al. The microbiology of infected pancreatic necrosis in the era of minimally invasive therapy. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2018;37(7):1353–1359.
    1. De Waele JJ, Rello J, Anzueto A, Moreno R, Lipman J, Sakr Y, et al. Infections and use of antibiotics in patients admitted for severe acute pancreatitis: data from the EPIC II study. Surg Infect. 2014;15(4):394–398.
    1. Maraví-Poma E, Gener J, Alvarez-Lerma F, Olaechea P, Blanco A, Domínguez-Muñoz JE, et al. Early antibiotic treatment (prophylaxis) of septic complications in severe acute necrotizing pancreatitis: a prospective, randomized, multicenter study comparing two regimens with imipenem-cilastatin. Intensive Care Med. 2003;29(11):1974–1980.
    1. Moka P, Goswami P, Kapil A, Xess I, Sreenivas V, Saraya A. Impact of Antibiotic-Resistant Bacterial and Fungal Infections in Outcome of Acute Pancreatitis. Pancreas. 2018;47(4):489–494.
    1. Kochhar R, Ahammed SKM, Chakrabarti A, Ray P, Sinha SK, Dutta U, et al. Prevalence and outcome of fungal infection in patients with severe acute pancreatitis. J Gastroenterol Hepatol. 2009;24(5):743–747.
    1. Schwender BJ, Kolwijck E. Risk factors for the development of intra-abdominal fungal infections in acute pancreatitis. Pancreas. 2015;44(5):805–807.
    1. Grewe M, Tsiotos GG, De-Leon EL, Sarr MG. Fungal infection in acute necrotizing pancreatitis. J Am College Surg. 1999;188(4):408–414.
    1. Wittau M. Intraabdominal tissue concentration of ertapenem. J Antimicrob Chemother. 2006;57(2):312–316.
    1. Brattström C, Malmborg AS, Tydén G. Penetration of imipenem into human pancreatic juice following single intravenous dose administration. Chemotherapy. 1989;35(2):83–87.
    1. Cheng MP, Stenstrom R, Paquette K, Stabler SN, Akhter M, Davidson AC, et al. Blood culture results before and after antimicrobial administration in patients with severe manifestations of sepsis: a diagnostic study. Ann Intern Med. 2019;171(8):547–554.
    1. Montravers P, Kantor E, Constantin J-M, Lefrant J-Y, Lescot T, Nesseler N, et al. Epidemiology and prognosis of anti-infective therapy in the ICU setting during acute pancreatitis: a cohort study. Crit Care. 2019;23(1):393.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa